Cytoplasmic Domains of the Human Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Receptor beta  Chain (hbeta c) Responsible for Human GM-CSF-induced Myeloid Cell Differentiation*

Tetsuya MatsuguchiDagger §, Michael B. Lilly, and Andrew S. KraftDagger parallel

From the Dagger  Division of Medical Oncology, University of Colorado Health Science Center, Denver, Colorado 80262 and the  Division of Medical Oncology, University of Washington and Veterans Affairs Medical Center, Seattle, Washington 98108

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates differentiation, survival, and proliferation of myeloid progenitor cells. The biologic actions of GM-CSF are mediated by its binding to the alpha  and beta  subunits of the GM-CSF receptor (GM-CSFRalpha and beta c, respectively). To determine whether identical regions of the beta c protein mediate both cell growth and differentiation, we expressed cDNA constructs encoding the human wild-type (897 amino acids) and truncated beta c (hbeta c) subunits along with the wild-type human GM-CSFRalpha subunit in the murine WT19 cell line, an FDC-P1-derived cell line that differentiates toward the monocytic lineage in response to murine GM-CSF. Whereas the WT19 cell line carrying the C-terminal deleted hbeta c subunit of 627 amino acids was still able to grow in human GM-CSF (hGM-CSF), 681 amino acids of the hbeta c were necessary for cell differentiation. The addition of hGM-CSF to WT19 cell lines containing the hbeta c627 subunit stimulated the phosphorylation of ERK (extracellular signal-regulated kinase) and induced the tyrosine-phosphorylation of SHP-2 and STAT5, suggesting that the activation of these molecules is insufficient to mediate the induction of differentiation. A point mutation of tyrosine 628 to phenylalanine (Y628F) within hbeta c681 abolished the ability of hGM-CSF to induce differentiation. Our results indicate that the signals required for hGM-CSF-induced differentiation and cell growth are mediated by different regions of the hbeta c subunit.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Granulocyte-macrophage colony-stimulating factor (GM-CSF)1 is secreted by activated T cells, endothelial cells, fibroblasts, mast cells, B cells, and macrophages and plays an important role in promoting differentiation, survival, and proliferation of colony-forming unit-granulocyte-macrophage (CFU-GM) progenitor cells. GM-CSF also enhances the function of mature neutrophils, monocytes, and eosinophils, and stimulates the burst-promoting activity for BFU-E (1-3). In addition, in murine models, alveolar proteinosis, a disease caused by excessive secretion of protein into the alveolar spaces, is associated with the deletion of the GM-CSF gene, suggesting that GM-CSF is essential for alveolar macrophage functions (4, 5).

The biologic actions of GM-CSF are mediated by its binding to a specific receptor consisting of alpha  and beta  subunits, both of which are members of the type I cytokine receptor family (6, 7). The alpha  subunit (GM-CSFRalpha ) binds GM-CSF with low affinity (6). The beta  subunit does not bind GM-CSF itself, but it forms a high affinity receptor in combination with the alpha  subunit (7). The beta  chain is referred to as the common beta  chain (beta c) because it is also utilized by interleukin 3 (IL-3) and interleukin 5 (IL-5) (8, 9).

We have recently reported that the cytoplasmic domain of the human GM-CSFRalpha (hGM-CSFRalpha ) is indispensable for cellular differentiation induced by human GM-CSF (hGM-CSF) (10). In addition, the cytoplasmic domain of the human beta c (hbeta c) has recently been demonstrated to be essential for hGM-CSF-mediated myeloid cell differentiation (11). However, the exact mechanism of differentiation by GM-CSF has not been clearly elucidated. In the present study, we examined the role of beta c in GM-CSF-mediated cell differentiation by using the murine WT19 cell line, an FDC-P1-derived cell line that uniformly differentiates toward the monocytic lineage in response to murine GM-CSF (mGM-CSF), but grows without differentiation in the presence of murine IL-3 (mIL-3) (10, 12). By expressing the wild-type and mutated hbeta c constructs along with the wild-type hGM-CSFRalpha in WT19 cells, we demonstrate the following results. 1) Mutation of the two prolines in the box 1 region of hbeta c, which are necessary for Jak2 activation, results in the loss of hGM-CSF-induced cell differentiation. 2) The hbeta c C-terminal truncation mutants demonstrate that 681 amino acids of the hbeta c are sufficient to mediate hGM-CSF-induced differentiation, but the truncation of the hbeta c subunit to amino acid 627 abolishes this differentiation response. In contrast, 559 amino acids of the hbeta c are sufficient for hGM-CSF-induced cell growth. 3) Within the hbeta c681 subunit, a point mutation of tyrosine 628 to phenylalanine abolishes the ability of hbeta c681 to induce differentiation. 4) The activation of either ERK or STAT5 by hGM-CSF does not correlate with the ability of hGM-CSF to induce myeloid cell differentiation. These results demonstrate that hGM-CSF-mediated cell growth and differentiation require distinct regions of the hbeta c cytoplasmic domain.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cells and Cell Culture-- The mouse IL-3 (mIL-3)-dependent WT19 cell line derived from the FDC-P1 cell line was a generous gift from Dr. Larry Rohrschneider (Fred Hutchinson Cancer Research Center, Seattle, WA) and was described previously (10, 12). The cells were cultured in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum and 10% WEHI-3B conditioned medium containing mIL-3.

Reagents-- Recombinant hGM-CSF was purchased from Immunex Corp. (Seattle, WA). Recombinant mGM-CSF and mIL-3 were obtained from Genzyme (Cambridge, MA). PD98059, a specific inhibitor of ERK kinase (MEK) was purchased from Alexis Corp. (San Diego, CA).

Plasmids-- The expression plasmid pEFBOS-hGM-CSFRalpha containing the wild-type hGM-CSFRalpha cDNA was a generous gift of Dr. N. A. Nicola (Walter and Eliza Hall Institute for Medical Research, Victoria, Australia). The wild-type human GM-CSFR beta  chain (hbeta c) cDNA was removed from the plasmid pKH97 (provided by Dr. A. Miyajima, DNAX Research Institute, Palo Alto, CA), and the 2.9-kilobase HindIII-NotI insert was ligated into pCEP4 (Invitrogen, Carlsbad, CA), which contains a hygromycin selection marker giving the plasmid pCEP4-hbeta cwt.

To construct pCEP4-hbeta c 832, 796, 681, 627, and 592, the wild-type BglII-XbaI fragment of pCEP4-hbeta cwt was replaced with the BglII-XbaI fragments of the PCR products generated with 5' primer, GCCTGACACGACTCCAGCTG, and 3' primer, GGAACTCTAGACTACTATGGCCCAAGAGCAGG (hbeta c832), TGCTCTAGATCAGGGCCCATTGAAGTCAAAGCT (hbeta c796), GGAACTCTAGACTACTATGGCCCAAGAGCAGG (hbeta c681), TGCTCTAGATCACTCCAGGGACCCTGGAGGTGG (hbeta c627), or TGCTCTAGATCAGGGCCCATTGAAGTCAAAGCT (hbeta c592).

To construct the pCEP4-hbeta c559 and pCEP4-hbeta c473, the wild-type BssHII-XbaI fragment of pCEP4-hbeta cwt was replaced with the BssHII-XbaI fragments of PCR products generated with 5' primer, TGGAGTGAGGCGCGCTCCTGGGACACCCAGTCGGTGCTG, and 3' primer, TGCTCTAGATCATGAGGCAGCTGGAGTCGTGTC (hbeta c559) or TGCTCTAGATCACTTTCTGCGCAGCCTGTACCC (hbeta c473).

The Y628F mutation was constructed by recombinant PCR (13) using four primers: CCAGGGTCCCTGGAGTTCCTGTGTCTG, CCCAGCAGGCAGACACAGGAACTCCAG, ATTGTTCCTTGGTGACCT, and GCCTGACACGACTCCAGCTG. The PCR product carrying the disrupted tyrosine was cloned into BglII/BstEII sites of pCEP4-hbeta cwt. To construct pCEP-hbeta c681Y628F, the wild-type BglII-XbaI fragment of pCEP4-hbeta cwt was replaced with the BglII-XbaI fragments of the PCR product using GCCTGACACGACTCCAGCTG (5' primer), GGAACTCTAGACTACTATGGCCCAAGAGCAGG (3' primer), and pCEP-hbeta c Y628F as the template. To construct pCEP-hbeta c PA which has the two prolines in the box 1 domain replaced with alanines, we used recombinant PCR using four primers: GAGGAGAAGATCGCCAACGCCAGCAAGAGCCAC, GTGGCTCTTGCTGGCGTTGGCGATCTTCTCCTC, TGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG, and CTGTGGGTAGATCTGAGGCAGCTGGAGTCGTGT. The PCR product carrying the disrupted prolines was cloned into the BssHII/BglII sites of pCEP4-hbeta c. The structure of the constructs was confirmed by restriction enzyme mapping and DNA sequence analysis.

Establishment of Stable Tranfectants-- 20 µg of pEFBOS-hGM-CSFRalpha was introduced into WT19 cells in combination with 1 µg of pSV2-Neo plasmid (14) by electroporation using Bio-Rad Gene Pulsar (Richmond, CA), and transfectants were isolated using G418 (0.4 mg/ml). A clone termed "WT19 pEFBOS-hGM-CSFRalpha " expressing hGM-CSFRalpha was used for the transfection of pCEP4-hbeta c wild-type or mutant constructs. Resistant clones expressing hbeta c were then isolated using hygromycin selection (0.4 mg/ml).

Antibodies-- The polyclonal and monoclonal anti-hbeta c antibodies, anti-ERK2 polyclonal antibody (specific to both ERK1 and 2) and the anti-Stat5b polyclonal antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The anti-STAT5b antibody did not cross-react with Stat5a (data not shown). The anti-Stat5a polyclonal antibody was obtained from R & D Systems (Minneapolis, MN) and does not cross-react with STAT5b (data not shown). The anti-phosphotyrosine monoclonal antibody (4G10) was purchased from Upstate Biotechnology (Lake Placid, NY). The phospho-specific anti-ERK polyclonal antibody was obtained from New England Biolabs (Beverly, MA). The anti-hGM-CSFRalpha monoclonal antibody was a generous gift of Dr. A. F. Lopez (Institute of Medical and Veterinary Science, Adelaide, Australia). The anti-F4/80 rat monoclonal antibody was purified from the culture supernatant of HB198 rat hybridoma cell line obtained from ATCC.

Immunoblotting-- Cells were lysed in PLC lysis buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 1 mM Na3VO4, 1 mM phenylmethanesulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin) at 108 cells/ml. The lysates were separated on SDS-polyacrylamide gels and then electrotransferred to Immobilon polyvinylidene difluoride membranes (Millipore, Bedford, MA). The membranes were blocked for 2 h in 2% bovine serum albumin-TBST (20 mM Tris-HCl, pH 7.6, 0.15 M sodium chloride, 0.1% Tween 20), incubated with primary antibodies in TBST for 1 h, washed three times with TBST, and incubated for 1 h with horseradish peroxidase-conjugated anti-mouse or rabbit immunoglobulin (Amersham Pharmacia Biotech) diluted 1:10,000 in TBST. After three washes in TBST, the blot was developed with the enhanced chemiluminescence system (Amersham Pharmacia Biotech) according to the manufacturer's instructions.

Immunoprecipitation-- The cell lysates were incubated with the indicated antibody for 2 h at 4 °C, followed by protein A-Sepharose beads (Amersham Pharmacia Biotech) for an additional 1 h at 4 °C. The beads were washed 3 times in PLC lysis buffer, suspended in SDS-sample buffer, and heated at 95 °C for 5 min. The eluted proteins were applied to an SDS-polyacrylamide gel and detected by Western blotting.

MTS Cell Proliferation Assay-- 5,000 cells were incubated in 100 µl of RPMI 1640 containing 10% fetal bovine serum and various concentrations of hGM-CSF for 14 h at 37 °C in a humidified 5% CO2 atmosphere. 20 µl of freshly prepared combined 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulhophenyl)-2H-tetrazolium, inner salt/phenazine methosulfate (MTS/PMS) solution (Promega, Madison, WI) were added to each sample. After an additional 4 h of incubation at 37 °C, the conversion of MTS into the aqueous soluble formazan was measured at an absorbance of 490 nm.

GST Fusion Protein and Affinity Purification-- GST-MycN262 (a generous gift from Dr. E. M. Blackwood, University of California, San Diego, La Jolla, CA) was described previously (15). GST-MycN262 fusion protein was induced with 0.2 mM isopropyl-beta -D-thiogalactopyranoside and purified over glutathione-Sepharose according to the manufacturer recommendations (Amersham Pharmacia Biotech).

Immune Complex Kinase Assay-- The cell lysates (1 × 107 cells/sample) were incubated with 0.4 µg of polyclonal anti-ERK2 antibody for 2 h at 4 °C, followed by protein A-Sepharose beads (Amersham Pharmacia Biotech) for an additional 1 h. The beads were washed 3 times in PLC lysis buffer and then once in kinase buffer (20 mM HEPES, pH7.9, 10 mM MgCl2, 0.2 mM EDTA, 0.5 mM sodium vanadate, 10 mM beta -glycerophosphate, and 1 mM dithiothreitol). The kinase reaction was initiated by the addition of 40 µl of kinase buffer with 20 µM ATP, 5 µCi of [gamma -32P]ATP, and 5 µg of GST-MycN262 and was allowed to proceed for 15 min at 30 °C. The reaction was terminated by the addition of 2× SDS sample buffer. Samples were boiled and resolved by SDS-PAGE, and the fixed gel was exposed to an x-ray film and the PhosphorImager (Molecular Dynamics).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Expression of Wild-type and Mutant hbeta c in WT19 Cells-- To study the role of hbeta c in hGM-CSF-mediated differentiation, we constructed a series of cytoplasmic deletion and point mutants of the hbeta c subunit (Fig. 1A). These mutant hbeta c subunits were transfected into WT19 cells expressing the wild-type hGM-CSFRalpha subunit (Fig. 1, B and C). The amino acid length of each hbeta c mutant represents the number of amino acids from the N terminus including the leader sequence. As evaluated by Western blotting and flow-cytometry, the expression level of each mutant hbeta c subunit in these clonal cell lines (Fig. 2, A and B) was found to be similar. The mutations introduced into the hbeta c cytoplasmic domain did not affect the high affinity ligand binding as reported by others (16) (data not shown). At least three clones were isolated expressing each hbeta c mutant and were analyzed in the following experiments (see below).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic structure of the hbeta c mutants. A, the extracellular domains are abbreviated. Positions of the tyrosine residues, the conserved box 1 and 2, and extended box 2 regions are indicated. Amino acid residues are numbered from the first methionine of the signal peptide. B, flow cytometric analysis of GM-CSFRalpha expression on WT19 pEFBOS-hGM-CSFRalpha cells. Cells were stained with either the anti-GM-CSFRalpha monoclonal antibody or the control antibody followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG. C, Western blotting analysis of hGM-CSFRalpha expression in WT19 pEFBOS-hGM-CSFRalpha cells. Cell lysates (3 × 106 cells/lane) were separated on a 7% SDS-PAGE gel and immunoblotted with the monoclonal anti-hGM-CSFRalpha antibody.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of hbeta c in WT19 transfectants. A, Western blotting analysis of hbeta c mutants expression in WT19 alpha beta transfectants. Cell lysates (3 × 106 cells/lane) were separated on a 7% SDS-PAGE gel and immunoblotted with the polyclonal anti-hbeta c antibody. B, flow cytometric analyses of hbeta c expression on WT19alpha beta transfectants. Cells were stained with either the anti-hbeta c monoclonal antibody or the control antibody followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG.

Induction of Monocytic Differentiation through hbeta c in WT19 Cells-- Parental WT19 cells growing in mIL-3 demonstrated a myeloblastic morphology including rounded nuclei, fine chromatin, and basophilic cytoplasm. In response to mGM-CSF, the cells demonstrated monocytic characteristics: an indented nucleus with fine stranded appearance, increased cytoplasm containing a variable number of vacuoles, and larger total cell size. WT-19 cells treated with mGM-CSF demonstrated significantly increased surface expression of F4/80, a marker of monocyte differentiation (17). As previously reported (10), hGM-CSF treatment of WT19alpha beta wt cells expressing hGM-CSFRalpha and the wild-type hbeta c subunits induced monocytic differentiation of WT19 cells, as measured by changes in morphology and the surface expression of F4/80 (Fig. 3, A and B).


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 3.   Monocytic differentiation of WT19 alpha beta transfectants with hGM-CSF treatment. A, morphological changes of WT19 transfectants in response to hGM-CSF. WT19alpha beta transfectants were maintained in mIL-3 alone (1 ng/ml) or mIL-3 + 10 ng/ml hGM-CSF. Wright staining was performed (original magnification × 400) on day 3. B, surface expression of the monocyte-specific F4/80 antigen on WT19 transfectants treated with hGM-CSF. WT19 transfectants were maintained in mIL-3 alone or mIL-3 + 10 ng/ml hGM-CSF for 3 days. The cell surface expression of monocytic specific F4/80 was analyzed by flow cytometry after staining with the monoclonal anti-F4/80 antibody and fluorescein isothiocyanate-labeled anti-rat Ig secondary antibody.

The type I cytokine receptors share amino acid sequence homology in a membrane proximal region called the box 1 region (18, 19). The box 1 region contains conserved prolines that are essential for Jak2 activation by various cytokines (20). To test whether these prolines are necessary for hGM-CSF-induced differentiation, they (Pro-479 and -481) were mutated to alanines and this receptor (hbeta cPA) was expressed along with the wild-type hGM-CSFRalpha in WT19 cells. The addition of hGM-CSF to this cell line (WT19alpha beta PA) failed to induce differentiation as measured by morphology and the lack of induction of F4/80 expression (Fig. 3, A and B), indicating that the prolines of the box 1 region are essential for hGM-CSF-mediated differentiation.

To determine which regions of hbeta c subunit are required for hGM-CSF-mediated cell differentiation and growth, additional truncation mutants were generated, and stable cell lines were isolated. Clear morphological differentiation was observed in WT19 cell lines expressing hbeta c subunits of 832, 796, or 681 amino acids in length when stimulated by hGM-CSF (Fig. 3A, Table I). In these cell lines, hGM-CSF induced the increase of F4/80 surface expression (Fig. 3B, Table I). In contrast, WT19 cells expressing hbeta c subunit containing 627 or fewer amino acids did not exhibit morphological differentiation or increased F4/80 expression in response to hGM-CSF (Fig. 3, Table I). These results suggest that the region between amino acids 627 and 681 of hbeta c is essential for hGM-CSF-induced cell differentiation of WT19 cells.

                              
View this table:
[in this window]
[in a new window]
 
Table I
The effects of hGM-CSF on WT19alpha beta transfectants

As phosphorylated tyrosines are important for the induction of cell growth and differentiation by several growth factor receptors (12, 21-23), the possibility that tyrosine residues of hbeta c681 were involved in the differentiation signal was examined next. Only one tyrosine (Tyr-628) is found between amino acids 627 and 681 of hbeta c subunit. To determine whether Tyr-628 is involved in differentiation signals, it was mutated to phenylalanine in the truncated hbeta c681. First, to examine if Tyr-628 of hbeta c is phosphorylated in response to hGM-CSF in WT19 cells, WT19alpha beta 681 and WT19alpha beta 681Y628F cells were stimulated with hGM-CSF, and the immunoprecipitated hbeta c was probed with either the anti-phosphotyrosine antibody or the anti-hbeta c antibody (Fig. 4). The anti-hbeta c immunoblot demonstrates that the expression levels of the two receptors in WT19 cells was similar, whereas the anti-phosphotyrosine immunoblot demonstrates that the hGM-CSF-mediated tyrosine phosphorylation of hbeta c681Y628F was 10% of that of hbeta c681. Therefore, Tyr-628 is the major tyrosine-phosphorylated site within the hbeta c681 subunit.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Tyrosine phosphorylation of hbeta c681 and hbeta c681Y628F in response to hGM-CSF stimulation. WT19alpha beta 681 and WT19alpha beta 681Y628F cells were cytokine-starved for 6 h and stimulated with 10 ng/ml of hGM-CSF for the indicated times. Cell extracts (1 × 107 cells/lane) were immunoprecipitated with the anti-hbeta c monoclonal antibody, separated by SDS-PAGE, and immunoblotted with the anti-phosphotyrosine antibody (top panel) or the anti-hbeta c polyclonal antibody (bottom panel).

Addition of hGM-CSF to clonal cell lines expressing this mutant, hbeta c681Y628F, failed to induce monocytic differentiation in response to hGM-CSF (Fig. 3, A and B). In comparison, when this identical point mutation was introduced into the full-length hbeta c subunit, hbeta cY628F, and expressed in WT19 cells, the cells differentiated normally in response to hGM-CSF (Fig. 3 A and B). These findings demonstrated that although Tyr-628 plays an important role in hGM-CSF-mediated cell differentiation in the truncated 681 amino acid receptor, the C-terminal region of the wild-type hbeta c may transmit a similar differentiation signal.

Proliferation and Differentiation Signals Are Mediated by Different Regions of hbeta c-- GM-CSF regulates both cell differentiation and proliferation of myeloid progenitor cells. To investigate whether differentiation and proliferation signals are generated by different or identical regions of the hbeta c subunit, the growth of each of the above mutants was examined at low concentrations (1-40 pg/ml) of hGM-CSF (Fig. 5). The growth response to hGM-CSF of WT19 cells containing hbeta c796 was similar to alpha beta wt cells. Cells containing the hbeta c627, hbeta c681, and hbeta c681Y628F transfectants grew at a reduced rate when compared with alpha beta wt cells incubated with comparable concentrations of hGM-CSF. Similar results were obtained with WT19 cells containing hbeta c559 and 592 (data not shown). However, alpha beta PA cells did not show any growth response to hGM-CSF (data not shown). Therefore, hGM-CSF-mediated signals for proliferation and differentiation are controlled by different regions of the hbeta c subunit.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   MTS proliferation assay of WT19 transfectants and parental WT19 cells. Cells (5,000 cells/sample) were incubated in RPMI 1640 containing 10% fetal bovine serum and various concentrations of hGM-CSF for 14 h at 37 °C. After MTS/PMS solution was added, cells were incubated for 4 h at 37 °C. The conversion of MTS was measured by the amount of 490 nm absorbance. Error bars from triplicate experiments are shown.

Activation of the MAP Kinase Pathway Is Not Sufficient to Stimulate hGM-CSF-induced Differentiation-- To determine which hGM-CSF-induced signals are important for growth and/or differentiation of WT19 cells, the signaling pathways activated by hGM-CSF were examined. Shc and SHP-2, when phosphorylated on tyrosines by GM-CSF stimulation, bind to the SH2-containing Grb2 protein (24, 25) and mediate the activation of the Ras-ERK pathway. hGM-CSF-induced tyrosine-phosphorylation of Shc, and SHP-2 was equivalent in WT19alpha beta wt, alpha beta 681, alpha beta 681Y628F and alpha beta 627 cell lines, suggesting that these proteins are similarly regulated in cells that are or are not capable of undergoing hGM-CSF-induced differentiation (Fig. 6, A and B). In contrast, cells that contain the box 1 proline mutant (hbeta cPA) were incapable of both Shc and SHP-2 phosphorylation (Fig. 6, A and B).


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 6.   Activation of the ERK pathway by hGM-CSF in WT19 transfectants. Cells were cytokine-starved for 6 h and stimulated by 10 ng/ml of hGM-CSF for 10 min. A, tyrosine phosphorylation of SHP-2 in response to hGM-CSF in WT19 transfectants. Cell extracts were immunoprecipitated with anti-SHP-2 antibody, and the Western blot was probed with anti-phosphotyrosine antibody (top panel) or anti-SHP-2 antibody (bottom panel). B, hGM-CSF-dependent phosphorylation of Shc in WT19 transfectants. Cell extracts were immunoprecipitated with anti-Shc antibody, and the Western blot was probed with anti-phosphotyrosine antibody (top panel) or anti-Shc antibody (bottom panel). C, lysates from 3 × 106 cells were separated on a 7.5% SDS-polyacrylamide gel and immunoblotted with the anti-phospho-ERK antibody (P-ERK, top panel) or the anti-ERK2 antibody (ERK, bottom panel).

ERK phosphorylation, a downstream event of Shc and SHP-2 phosphorylation, was examined in WT19alpha beta cells by immunoblotting with an antibody specifically raised against phosphorylated forms of ERKs (Fig. 6C). hGM-CSF addition to these WT19 clones induced ERK phosphorylation in alpha beta 681Y628F and alpha beta 627 cells to a level similar to that seen in alpha beta wt and alpha beta 681 cells (Fig. 6C). ERK phosphorylation was not seen in clones containing hbeta c473 or hbeta cPA, which has two prolines in the box 1 domain replaced with alanines. As the phosphorylation of tyrosine residues in the activation loop of ERKs occurs with the kinase activation of these proteins (26), these data suggest that activation of ERKs does not correlate with hGM-CSF-induced differentiation.

The role of ERKs in the induction of cell differentiation is controversial (23, 27-30). WT19 cells containing a C-terminal truncation mutant of hGM-CSFRalpha subunit and the wild-type hbeta c subunit, hGM-CSF were capable of differentiation, but not ERK activation, in response to hGM-CSF (10). To further examine the role of the ERK pathway in the induction of differentiation, WT19 cells were treated with PD98059, a specific inhibitor of (MEK), prior to the addition of mGM-CSF. Although PD98059 addition to mGM-CSF-treated WT19 cells caused a 3-fold decrease in the activity of immunoprecipitated ERKs to phosphorylate GST-myc in vitro (Fig. 7A), this compound had no effect on the mGM-CSF-mediated differentiation of WT19 cells, as evidenced by the induction of F4/80 and morphologic changes (Fig. 7, B and C). Although the possibility that a small amount of ERK activity persists after PD98059 treatment in vivo cannot be ruled out by this experiment, these results suggest that full activation of the ERK pathway is neither sufficient nor necessary for GM-CSF-induced differentiation of WT19 cells.


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 7.   The effect of PD98059, a specific MEK inhibitor, on mGM-CSF-mediated differentiation of WT19 cells. A, immune complex kinase assay. WT19 cells were cytokine-starved for 6 h, treated with or without PD98059 (50 µM) for 30 min, followed by addition of 10 ng/ml of mGM-CSF for 10 min. ERK2 was immunoprecipitated from 1 × 107 cells, and a kinase reaction was performed using GST-MycN262 as an substrate. The degree of activation is indicated. B and C, the effect of PD98059 on mGM-CSF-induced monocytic differentiation of WT19 cells. WT19 cells were maintained in mIL-3 alone (1 ng/ml), mIL-3 + 10 ng/ml hGM-CSF, or mIL-3 + 10 ng/ml hGM-CSF + 50 µM PD98059 for 3 days. The monocytic cell differentiation was measured by cell morphology (B), and the surface expression of monocytic specific F4/80 antigen was analyzed by flow cytometry (C).

Tyrosine Phosphorylation of STAT5 Proteins Is Not Sufficient to Mediate hGM-CSF-induced Differentiation-- An important substrate of the Jak2 proteins whose tyrosine phosphorylation is induced by the addition of hGM-CSF is STAT5 (31). To determine whether STAT5 activation is sufficient to induce the differentiated phenotype, tyrosine phosphorylation of STAT5 proteins by hGM-CSF in the mutant hbeta c cell lines was examined. Stat5 consists of two proteins, Stat5a and Stat5b, encoded by separate genes, both of which have been shown to be activated by GM-CSF (31). To investigate the hGM-CSF-mediated activation of Stat5 proteins, immunoprecipitations were performed using specific antibodies against Stat5a or 5b from hGM-CSF-stimulated cell lysates followed by immunoblotting with the anti-phosphotyrosine antibody. Both Stat5a and 5b were phosphorylated on tyrosine after hGM-CSF treatment in WT19alpha beta wt and 681 cells, which respond to hGM-CSF with differentiation, and in WT19alpha beta 627 and alpha beta 681Y628F cells, which do not differentiate (Fig. 8). These results suggest that the activation of Stat5 proteins is not sufficient to induce differentiation of WT19 cells.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 8.   Tyrosine phosphorylation of Stat5a and Stat5b in response to hGM-CSF in WT19 transfectants. Cell extracts (1 × 107 cells/lane) were immunoprecipitated with anti-Stat5a (A) or anti-Stat5b antibody (B), separated by SDS-PAGE, and immunoblotted with the anti-phosphotyrosine antibody (top panel) or the anti-Stat5 antibodies (bottom panel).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

By expressing truncated forms of hbeta c in WT19 cells, we demonstrated that hGM-CSF-induced morphological differentiation and the surface expression of F4/80 requires hbeta c subunits of 832, 796, or 681 amino acids in length (Fig. 3, Table I). In contrast, WT19 cells expressing hbeta c subunit containing 627 amino acids or less did not differentiate but were capable of growth in the presence of hGM-CSF (Fig. 3). Mutation of the two prolines in the box 1 region blocked both growth and differentiation. Thus, these results suggest that cell growth and differentiation are mediated by different regions of the receptor and that the signals generated by the box 1 region of the receptor are necessary for both cellular events.

Similar results to those described above have been generated using M1 and WEHI-3B D+ cells as a target cell population for transfection (11). In this study, wild-type hbeta c and hbeta c783, but not hbeta c541 or 461, could mediate hGM-CSF-induced morphological change and differentiation marker induction, whereas induction of cell differentiation by hbeta c626 required a 50- to 100-fold higher concentration of hGM-CSF (M1 cells). However, in the WT19 cell system, neither hbeta c627 nor hbeta c681Y628F could induce cell differentiation even at a very high concentration (1 µg/ml) of hGM-CSF (data not shown). The results derived from M1 cells suggest that the region between amino acids 627 and 783 is necessary for the full differentiation signal, whereas our results more narrowly delineate the crucial region for differentiation to lie between 628 and 681.

The results described here demonstrate that tyrosine 628 is highly phosphorylated after hGM-CSF treatment in vivo (Fig. 4). In the hbeta c681 construct, this phosphotyrosine is essential for differentiation. Tyr-627 and its surrounding amino acids are conserved between human and mouse beta c (SLEYLCL), suggesting that in both species this tyrosine may play an important role in differentiation. In the macrophage colony stimulating factor signaling, both Tyr-807 and Tyr-721 of macrophage colony stimulating factor receptor were shown to be necessary for monocytic differentiation and for the tyrosine phosphorylation of phospholipase C-gamma (PLCgamma ) (12, 22). The involvement of PLCgamma in M-CSF-mediated cell differentiation was further demonstrated by the inhibition of differentiation using U-73122, a compound that acts as a specific inhibitor of PLCgamma (22). The surrounding amino acid sequence of hbeta c Tyr-628 (YLCL) is homologous to the optimal binding site for the N-terminal SH2 domain of PLCgamma in a phosphopeptide binding assay (32). However, PLCgamma may not be involved in GM-CSF-induced differentiation as suggested by the following data. First, tyrosine phosphorylation of PLCgamma was not induced by addition of hGM-CSF to WT19 cells (data not shown) or another myeloid cell line treated with this hormone (33), although M-CSF induced significant tyrosine phosphorylation of PLCgamma . Second, U-73122 did not inhibit the differentiation of WT19 cells by mGM-CSF at 1 µM, a concentration 10 times higher than that capable of inhibiting the M-CSF-mediated differentiation (22) (data not shown).

Although the single tyrosine mutation in the 681 hbeta c containing cell line had significant biologic effects, this mutation had no significant effect on differentiation in the wild-type receptor. The wild-type hbeta c contains four tyrosines C-terminal to Tyr-628. One of them (Tyr-882) has a similar amino acid sequence (YLSL) to Tyr-628 (YLCL). Two of them (Tyr-766 and Tyr-842) have a leucine at the +3 amino acid (YVEL and YCFL, respectively). The amino acid at +3 position of the tyrosine is important in dictating the binding affinity for many SH2 domain-containing proteins (32). It is possible that a common signaling molecule binds to a number of tyrosines in the hbeta c-mediating cell differentiation so that, in the wild-type receptor, mutation of a single tyrosine is not sufficient to abolish cell differentiation.

The role of ERKs in differentiation appears to be complex and may depend on the cell type and the stimulus involved. The ERK pathway has been suggested to be essential for the neurite outgrowth of PC12 cells (27, 34). Also, interleukin 6 (IL-6) can induce PC12 differentiation when the cells are pretreated with nerve growth factor (35). A mutation of a specific tyrosine in gp130, the IL-6 receptor signaling subunit involved in ERK activation, abolishes the induction of cell differentiation by IL-6 (23). Our results suggest that the ERK pathway may not be involved in hGM-CSF-mediated differentiation of WT19 cells. 1) Although Tyr-628 of hbeta c was shown to be a binding site for SHP-2 SH2 domains (36), it was not necessary for hGM-CSF-induced tyrosine phosphorylation of SHP-2 or ERK activation (Fig. 6) (36). 2) PD98059, a specific inhibitor of MEK, blocked activation, but this compound had no significant effect on differentiation. 3) The expression of a constitutively active mutant of MEK in WT19 cells did not induce differentiation.2 Thus, activation of ERK does not appear to be sufficient or necessary for hGM-CSF-induced differentiation of WT19 cells.

Activation of Stat proteins by several cytokines has been suggested to be involved in cell differentiation (37-42). In WT19 cells transfected with hGM-CSFRalpha and wild-type hbeta c, hGM-CSF induced tyrosine phosphorylation of both isoforms of Stat5, but not other Stat proteins (Stat1, Stat3, and Stat6 examined). Tyr-628 was not necessary for the hGM-CSF-mediated tyrosine phosphorylation of either Stat5a or 5b. In addition, both hbeta c628 and hbeta c681Y628F could induce tyrosine phosphorylation of Stat5a and 5b in response to hGM-CSF equivalent to that seen in WT19 cells containing the wild-type receptor (Fig. 8). These results suggest that Stat5 activation is not sufficient for the induction of cellular differentiation. In a recent report, using chimeric receptors of erythropoietin and IL-3, a delayed activation of Stat5 was suggested to be important for the erythroid differentiation induction of BaF/3 cells (43). However, we did not see a delay in the time course of Stat5 activation in WT19 transfectants which differentiate in response to hGM-CSF in contrast to those cell lines which are capable of only growth (data not shown). Thus, none of the signals examined (STAT5 activation along with SHP-2 and Shc phosphorylation) are sufficient to modulate differentiation.

In conclusion, our data suggest that cell differentiation and cell growth induced by hGM-CSF are mediated by different regions of the hbeta c subunit. Attempts are underway to define the novel signals generated by amino acids 627-681 of the hbeta c which control the differentiated phenotype.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK44741 (to A. S. K.) and CA45672 (to M. B. L.) and a Veterans Affairs Merit Award (to M. B. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by direct grants from the University of Alabama and the University of Colorado.

parallel To whom correspondence should be addressed: Division of Medical Oncology, University of Colorado Health Science Center, 4200 East Ninth Ave., Denver, CO 80262. Tel.: 303-315-8802; Fax: 303-315-8825.

1 The abbreviations used are: GM-CSF, granulocyte-macrophage colony-stimulating factor; GM-CSFR, GM-CSF receptor; hGM-CSF, human GM-CSF; mGM-CSF, murine GM-CSF; ERK, extracellular signal-regulated kinase; IL, interleukin; MEK, ERK kinase; PCR, polymerase chain reaction; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulhophenyl)-2H-tetrazolium, inner salt; PMS, phenazine methosulfate; PLC, phospholipase C; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis.

2 T. Matsuguchi and A.Kraft, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Baldwin, G. C. (1992) Dev. Biol. 151, 352-367[Medline] [Order article via Infotrieve]
  2. Gasson, J. C. (1991) Blood 77, 1131-1145[Medline] [Order article via Infotrieve]
  3. Emerson, S. G., Thomas, S., Ferrara, J. L., and Greenstein, J. L. (1989) Blood 74, 49-55[Abstract]
  4. Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., Dickersin, G. R., Bachurski, C. J., Mark, E. L., Whitsett, J. A., et al.. (1994) Science 264, 713-716[Medline] [Order article via Infotrieve]
  5. Stanley, E., Lieschke, G. J., Grail, D., Metcalf, D., Hodgson, G., Gall, J. A., Maher, D. W., Cebon, J., Sinickas, V., and Dunn, A. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5592-5596[Abstract]
  6. Gearing, D. P., King, J. A., Gough, N. M., and Nicola, N. A. (1989) EMBO J. 8, 3667-3676[Abstract]
  7. Hayashida, K., Kitamura, T., Gorman, D. M., Arai, K., Yokota, T., and Miyajima, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9655-9659[Abstract]
  8. Kitamura, T., Sato, N., Arai, K., and Miyajima, A. (1991) Cell 66, 1165-1174[Medline] [Order article via Infotrieve]
  9. Tavernier, J., Devos, R., Cornelis, S., Tuypens, T., Van der Heyden, J., Fiers, W., and Plaetinck, G. (1991) Cell 66, 1175-1184[Medline] [Order article via Infotrieve]
  10. Matsuguchi, T., Zhao, Y., Lilly, M. B., and Kraft, A. S. (1997) J. Biol. Chem. 272, 17450-17459[Abstract/Free Full Text]
  11. Smith, A., Metcalf, D., and Nicola, N. A. (1997) EMBO J. 16, 451-464[Abstract/Free Full Text]
  12. Bourette, R. P., Myles, G. M., Carlberg, K., Chen, A. R., and Rohrschneider, L. R. (1995) Cell Growth Differ. 6, 631-645[Abstract]
  13. Ishizaka-Ikeda, E., Fukunaga, R., Wood, W. I., Goeddel, D. V., and Nagata, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 123-127[Abstract]
  14. Ochi, A., Hawley, R. G., Hawley, T., Shulman, M. J., Traunecker, A., Kohler, G., and Hozumi, N. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 6351-6355[Abstract]
  15. Luscher, B., and Eisenman, R. N. (1992) J. Cell Biol. 118, 775-784[Abstract]
  16. Sakamaki, K., Miyajima, I., Kitamura, T., and Miyajima, A. (1992) EMBO J. 11, 3541-3549[Abstract]
  17. Austyn, J. M., and Gordon, S. (1981) Eur. J. Immunol. 11, 805-815[Medline] [Order article via Infotrieve]
  18. Fukunaga, R., Ishizaka-Ikeda, E., Pan, C. X., Seto, Y., and Nagata, S. (1991) EMBO J. 10, 2855-2865[Abstract]
  19. Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T., and Kishimoto, T. (1991) Proc Natl Acad Sci U. S. A. 88, 11349-11353[Abstract]
  20. Stahl, N., and Yancopoulos, G. D. (1993) Cell 74, 587-590[Medline] [Order article via Infotrieve]
  21. Wakao, H., Chida, D., Damen, J. E., Krystal, G., and Miyajima, A. (1997) Biochem. Biophys. Res. Commun. 234, 198-205[CrossRef][Medline] [Order article via Infotrieve]
  22. Bourette, R. P., Myles, G. M., Choi, J. L., and Rohrschneider, L. R. (1997) EMBO J. 16, 5880-5893[Abstract/Free Full Text]
  23. Ihara, S., Nakajima, K., Fukada, T., Hibi, M., Nagata, S., Hirano, T., and Fukui, Y. (1997) EMBO J. 16, 5345-5352[Abstract/Free Full Text]
  24. Matsuguchi, T., Salgia, R., Hallek, M., Eder, M., Druker, B., Ernst, T. J., and Griffin, J. D. (1994) J. Biol. Chem. 269, 5016-5021[Abstract/Free Full Text]
  25. Welham, M. J., Dechert, U., Leslie, K. B., Jirik, F., and Schrader, J. W. (1994) J. Biol. Chem. 269, 23764-23768[Abstract/Free Full Text]
  26. Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., and Yancopoulos, G. D. (1991) Cell 65, 663-675[Medline] [Order article via Infotrieve]
  27. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994) Cell 77, 841-852[Medline] [Order article via Infotrieve]
  28. Melemed, A. S., Ryder, J. W., and Vik, T. A. (1997) Blood 90, 3462-3470[Abstract/Free Full Text]
  29. Vaillancourt, R. R., Heasley, L. E., Zamarripa, J., Storey, B., Valius, M., Kazlauskas, A., and Johnson, G. L. (1995) Mol. Cell. Biol. 15, 3644-3653[Abstract]
  30. Schultz, H., Engel, K., and Gaestel, M. (1997) J. Cell. Physiol. 173, 310-318[CrossRef][Medline] [Order article via Infotrieve]
  31. Mui, A. L., Wakao, H., O'Farrell, A. M., Harada, N., and Miyajima, A. (1995) EMBO J. 14, 1166-1175[Abstract]
  32. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Brige, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993) Cell 72, 767-778[Medline] [Order article via Infotrieve]
  33. Hallek, M., Ando, K., Eder, M., Slattery, K., Ajchenbaum-Cymbalista, F., and Griffin, J. D. (1994) Leukemia (Baltimore) 8, 740-748[Medline] [Order article via Infotrieve]
  34. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 13585-13588[Abstract/Free Full Text]
  35. Ihara, S., Iwamatsu, A., Fujiyoshi, T., Komi, A., Yamori, T., and Fukui, Y. (1996) J. Biochem. (Tokyo) 120, 865-868[Abstract]
  36. Bone, H., Dechert, U., Jirik, F., Schrader, J. W., and Welham, M. J. (1997) J. Biol. Chem. 272, 14470-14476[Abstract/Free Full Text]
  37. Shimozaki, K., Nakajima, K., Hirano, T., and Nagata, S. (1997) J. Biol. Chem. 272, 25184-25189[Abstract/Free Full Text]
  38. Boccaccio, C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., and Comoglio, P. M. (1998) Nature 391, 285-288[CrossRef][Medline] [Order article via Infotrieve]
  39. Piekorz, R. P., and Hocke, G. M. (1997) Cytokine 9, 639-649[CrossRef][Medline] [Order article via Infotrieve]
  40. Wu, Y. Y., and Bradshaw, R. A. (1996) J. Biol. Chem. 271, 13023-13032[Abstract/Free Full Text]
  41. Woldman, I., Mellitzer, G., Kieslinger, M., Buchhart, D., Meinke, A., Beug, H., and Decker, T. (1997) J. Immunol. 159, 877-886[Abstract]
  42. Matsumura, I., Ishikawa, J., Nakajima, K., Oritani, K., Tomiyama, Y., Miyagawa, J., Kato, T., Miyazaki, H., Matsuzawa, Y., and Kanakura, Y. (1997) Mol. Cell. Biol. 17, 2933-2943[Abstract]
  43. Pless, M., Norga, K., Carroll, M., Heim, M. H., D'Andrea, A. D., and Mathey-Prevot, B. (1997) Blood 89, 3175-3185[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.